Efficacy and safety of Suyin Jiedu Granule in the treatment of chronic kidney disease stage 3-5: a multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052362

Enrollment

Unknown

Registered

2021-10-24

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease stage 3-5

Interventions

Treatment group:Basic treatment + Su Yin Jiedu granule (20g, tid)

Control group:Basic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic and staging criteria of CKD stage 3-5 formulated by KDIGO, does not enter dialysis, and the TCM syndrome differentiation is Shenxu Zhuodu syndrome; 2. Between the age of 18 and 80, regardless of gender; 3. Infection, acidosis, electrolyte disorder, hypertension and hyperlipidemia are effectively controlled; 4. The informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1. Various secondary kidney diseases, such as lupus nephritis, henoch-schonlein purpura nephritis, systemic small vascular inflammatory kidney damage, diabetic nephropathy, hypertensive kidney injury, gout nephropathy, myeloma nephropathy, etc.; 2. Those who are currently using hormones, immunosuppressants, Tripterysium Glycosides, etc., and it is difficult to stop using; 3. Serious primary diseases of the heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival; 4. Pregnant or lactating women; 5. Allergic constitution or known to be allergic to the composition of the drug we used in this study; 6. Persons with mental or legal disabilities; 7. Those who have no fixed place to work and are easy to fall off; 8. Suspected or true history of alcohol or drug abuse; 9. Participating in another clinical trail.

Design outcomes

Primary

Measure	Time frame
Serum creatinine;Estimate glomerular filtration rate;24-hour urinary protein quantity;TCM syndrome integral;	—

Secondary

Measure	Time frame
Urinary red blood cell;Hemoglobin;Serum albumin;Blood urea nitrogen;Cystatin C;Blood uric acid;Triacylglycerol;Total cholesterol;Low density lipoprotein cholesterol;	—

Countries

China

Contacts

Public ContactZhou Enchao

Affiliated Hospital of Nanjing University of Chinese Medicine

zhouenchao@njucm.edu.cn+86 13851572603

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026